RPRX SEC Filing News — Royalty Pharma plc

Latest SEC filings for Royalty Pharma plc (RPRX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-05.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ…
Sector: Healthcare Industry: Biotechnology Market Cap: $35.2B CIK: 1802768
20
Total Filings
0
Bullish Classifications
10
Bearish Classifications
11
Insider Transactions
1
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for RPRX currently lean bearish. Of the 20 filing records displayed, 10 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
RPRX Filing Activity Snapshot 2026-07-02 — 2026-10-05
Insider Transactions (Form 4)
0 buys vs 6 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$11.93M
Errol B. De Souza · 2026-08-12
206,352 shares · Form 144
Form 144 Notices
7
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Royalty Pharma plc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 6 open-market sale and 5 compensation award. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×6
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×5
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Open-market sale Insider Selling 2026-10-05

RPRX insider Urist Marshall (EVP, Research & Investments) sold 4,126 shares (~$235.6K)

Urist Marshall, listed as EVP, Research & Investments at Royalty Pharma plc, reported an open-market sale of 4,126 RPRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 4,126 $57.10 $235.6K
Filing: Form 4 (Insider Transaction) Insider: Urist Marshall (EVP, Research & Investments) Shares: 4,126 Est. Value: $235.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-09-30

RPRX insider Form 4 filed for equity award, exercise, or tax withholding

Bassler Bonnie L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 642 $58.41 $37.5K
Filing: Form 4 (Insider Transaction) Insider: Bassler Bonnie L (Director) Shares: 642
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-30

RPRX insider Urist Marshall (EVP, Research & Investments) sold 4,126 shares (~$238.8K)

Urist Marshall, listed as EVP, Research & Investments at Royalty Pharma plc, reported an open-market sale of 4,126 RPRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 4,126 $57.88 $238.8K
Filing: Form 4 (Insider Transaction) Insider: Urist Marshall (EVP, Research & Investments) Shares: 4,126 Est. Value: $238.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-24

RPRX insider Hite Christopher (EVP & Chairman, Partnering) sold 100,000 shares (~$5.85M)

Hite Christopher, listed as EVP & Chairman, Partnering at Royalty Pharma plc, reported an open-market sale of 100,000 RPRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 96,073 $58.51 $5.62M
S Open-market sale 3,927 $58.93 $231.4K
Filing: Form 4 (Insider Transaction) Insider: Hite Christopher (EVP & Chairman, Partnering) Shares: 100,000 Est. Value: $5.85M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-19

RPRX insider Hite Christopher (EVP & Chairman, Partnering) sold 100,000 shares (~$6.00M)

Hite Christopher, listed as EVP & Chairman, Partnering at Royalty Pharma plc, reported an open-market sale of 100,000 RPRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 100,000 $59.97 $6.00M
G Gift 16,800 — —
Filing: Form 4 (Insider Transaction) Insider: Hite Christopher (EVP & Chairman, Partnering) Shares: 100,000 Est. Value: $6.00M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-17

RPRX insider Coyne Terrance P. (EVP & CFO) sold 11,002 shares (~$645.6K)

Coyne Terrance P., listed as EVP & CFO at Royalty Pharma plc, reported an open-market sale of 11,002 RPRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 9,230 $58.59 $540.8K
S Open-market sale 1,772 $59.14 $104.8K
Filing: Form 4 (Insider Transaction) Insider: Coyne Terrance P. (EVP & CFO) Shares: 11,002 Est. Value: $645.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-08-07

RPRX insider Form 4 filed for equity award, exercise, or tax withholding

Legorreta Pablo G. (Director, CEO, Chairman of the Board) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 65,216 — —
G Gift derivative · LP interests in RPI US Partners 2019, LP 30,000 — —
Filing: Form 4 (Insider Transaction) Insider: Legorreta Pablo G. (Director, CEO, Chairman of the Board) Shares: 65,216
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-08-07

RPRX insider Form 4 filed for equity award, exercise, or tax withholding

Coyne Terrance P. (EVP & CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 11,002 — —
G Gift derivative · Class E Ordinary Shares 18,500 — —
Filing: Form 4 (Insider Transaction) Insider: Coyne Terrance P. (EVP & CFO) Shares: 11,002
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-08-07

RPRX insider Form 4 filed for equity award, exercise, or tax withholding

Hite Christopher (EVP & Chairman, Partnering) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 11,002 — —
Filing: Form 4 (Insider Transaction) Insider: Hite Christopher (EVP & Chairman, Partnering) Shares: 11,002
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-08-07

RPRX insider Form 4 filed for equity award, exercise, or tax withholding

Urist Marshall (EVP, Research & Investments) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,252 — —
G Gift derivative · LP interests in RPI US Partners 2019, LP 3,000 — —
Filing: Form 4 (Insider Transaction) Insider: Urist Marshall (EVP, Research & Investments) Shares: 8,252
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-02

RPRX insider Urist Marshall (EVP, Research & Investments) sold 9,099 shares (~$508.5K)

Urist Marshall, listed as EVP, Research & Investments at Royalty Pharma plc, reported an open-market sale of 9,099 RPRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 9,099 $55.88 $508.5K
Filing: Form 4 (Insider Transaction) Insider: Urist Marshall (EVP, Research & Investments) Shares: 9,099 Est. Value: $508.5K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 7 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Royalty Pharma plc has 7 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-05

RPRX Form 144 filed for proposed insider sale by Urist Marshall (4,126 shares) ~$235.6K

Urist Marshall filed a Form 144 with the SEC indicating intent to sell RPRX (Royalty Pharma plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Urist Marshall Shares: 4,126 Est. Value: $235.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-28

RPRX Form 144 filed for proposed insider sale by Urist Marshall (4,126 shares) ~$238.8K

Urist Marshall filed a Form 144 with the SEC indicating intent to sell RPRX (Royalty Pharma plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Urist Marshall Shares: 4,126 Est. Value: $238.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-09-22

RPRX Form 144 filed for proposed insider sale by SCH Investment Partners LLC (100,000 shares) ~$5.85M

SCH Investment Partners LLC filed a Form 144 with the SEC indicating intent to sell RPRX (Royalty Pharma plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: SCH Investment Partners LLC Shares: 100,000 Est. Value: $5.85M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-18

RPRX Form 144 filed for proposed insider sale by SCH Investment Partners LLC (100,000 shares) ~$6.01M

SCH Investment Partners LLC filed a Form 144 with the SEC indicating intent to sell RPRX (Royalty Pharma plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: SCH Investment Partners LLC Shares: 100,000 Est. Value: $6.01M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-13

RPRX Form 144 filed for proposed insider sale by Terrance Coyne (11,002 shares) ~$644.3K

Terrance Coyne filed a Form 144 with the SEC indicating intent to sell RPRX (Royalty Pharma plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Terrance Coyne Shares: 11,002 Est. Value: $644.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-12

RPRX Form 144 filed for proposed insider sale by Errol B. De Souza (206,352 shares) ~$11.93M

Errol B. De Souza filed a Form 144 with the SEC indicating intent to sell RPRX (Royalty Pharma plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Errol B. De Souza Shares: 206,352 Est. Value: $11.93M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-12

RPRX Form 144 filed for proposed insider sale by Errol B. De Souza (125,000 shares) ~$7.22M

Errol B. De Souza filed a Form 144 with the SEC indicating intent to sell RPRX (Royalty Pharma plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Errol B. De Souza Shares: 125,000 Est. Value: $7.22M
View on SEC EDGAR → Open Filing Document →
Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Royalty Pharma plc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-05

RPRX filed 8-K — material company event

Royalty Pharma plc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Royalty Pharma plc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

RPRX filed Quarterly Report (10-Q)

Royalty Pharma plc filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Royalty Pharma plc's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on RPRX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — RPRX SEC Filings

More Tools for RPRX

RPRX Full Stock Analysis RPRX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper RPRX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the RPRX stock analysis page.

RPRX Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer